Tags

Type your tag names separated by a space and hit enter

Treprostinil for the treatment of pulmonary arterial hypertension.
Expert Rev Cardiovasc Ther. 2013 Jan; 11(1):13-25.ER

Abstract

Pulmonary arterial hypertension (PAH) is a progressive and fatal disease characterized by increasing pulmonary vascular resistance leading to right ventricular failure and death. Treprostinil is a stable prostacyclin analog approved for the treatment of PAH to improve exercise capacity. In the setting of PAH, the major pharmacological actions of treprostinil include vasodilatation of the pulmonary and systemic vascular beds, inhibition of platelet aggregation and inhibition of smooth muscle cell proliferation. Treprostinil therapy may be delivered via parenteral (subcutaneous and intravenous) or inhaled routes of administration, with oral tablets in the later stages of clinical development. In clinical trials, treprostinil has been shown to improve clinical status, functional class, exercise capacity and quality of life. Common side effects of treprostinil therapy include headache, flushing, jaw pain, diarrhea, and for subcutaneous administration, infusion site pain or reaction. This article provides an overview of treprostinil therapy for the treatment of PAH with a focus on the available efficacy and safety data for parenteral, inhaled and oral administration.

Authors+Show Affiliations

UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23259441

Citation

Torres, Fernando, and Lewis J. Rubin. "Treprostinil for the Treatment of Pulmonary Arterial Hypertension." Expert Review of Cardiovascular Therapy, vol. 11, no. 1, 2013, pp. 13-25.
Torres F, Rubin LJ. Treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2013;11(1):13-25.
Torres, F., & Rubin, L. J. (2013). Treprostinil for the treatment of pulmonary arterial hypertension. Expert Review of Cardiovascular Therapy, 11(1), 13-25. https://doi.org/10.1586/erc.12.160
Torres F, Rubin LJ. Treprostinil for the Treatment of Pulmonary Arterial Hypertension. Expert Rev Cardiovasc Ther. 2013;11(1):13-25. PubMed PMID: 23259441.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treprostinil for the treatment of pulmonary arterial hypertension. AU - Torres,Fernando, AU - Rubin,Lewis J, PY - 2012/12/25/entrez PY - 2012/12/25/pubmed PY - 2013/5/29/medline SP - 13 EP - 25 JF - Expert review of cardiovascular therapy JO - Expert Rev Cardiovasc Ther VL - 11 IS - 1 N2 - Pulmonary arterial hypertension (PAH) is a progressive and fatal disease characterized by increasing pulmonary vascular resistance leading to right ventricular failure and death. Treprostinil is a stable prostacyclin analog approved for the treatment of PAH to improve exercise capacity. In the setting of PAH, the major pharmacological actions of treprostinil include vasodilatation of the pulmonary and systemic vascular beds, inhibition of platelet aggregation and inhibition of smooth muscle cell proliferation. Treprostinil therapy may be delivered via parenteral (subcutaneous and intravenous) or inhaled routes of administration, with oral tablets in the later stages of clinical development. In clinical trials, treprostinil has been shown to improve clinical status, functional class, exercise capacity and quality of life. Common side effects of treprostinil therapy include headache, flushing, jaw pain, diarrhea, and for subcutaneous administration, infusion site pain or reaction. This article provides an overview of treprostinil therapy for the treatment of PAH with a focus on the available efficacy and safety data for parenteral, inhaled and oral administration. SN - 1744-8344 UR - https://www.unboundmedicine.com/medline/citation/23259441/Treprostinil_for_the_treatment_of_pulmonary_arterial_hypertension_ L2 - http://www.tandfonline.com/doi/full/10.1586/erc.12.160 DB - PRIME DP - Unbound Medicine ER -